Published in Neurology on July 17, 2013
Patent Foramen Ovale Closure in Older Patients (PFO-Elderly) | NCT04780022
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials. J Am Coll Cardiol (2016) 1.55
Recurrent stroke predictors differ in medically treated patients with pathogenic vs. other PFOs. Neurology (2014) 1.49
Controversies in cardioembolic stroke. Curr Treat Options Cardiovasc Med (2015) 0.90
Patent Foramen Ovale and Stroke-Current Status. J Stroke (2015) 0.83
Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J (2015) 0.82
Secondary stroke prevention: challenges and solutions. Vasc Health Risk Manag (2015) 0.79
Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice. Front Neurol (2016) 0.78
Determinants of antithrombotic choice for patent foramen ovale in cryptogenic stroke. Neurology (2014) 0.78
The RoPE Score and Right-to-Left Shunt Severity by Transcranial Doppler in the CODICIA Study. Cerebrovasc Dis (2015) 0.77
Cardioembolic Stroke. Circ Res (2017) 0.75
The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology (2016) 0.75
Response to letter regarding article, "Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials". Stroke (2013) 0.75
An Approach to Working Up Cases of Embolic Stroke of Undetermined Source. J Am Heart Assoc (2016) 0.75
Prevention of recurrent stroke in patients with patent foramen ovale. Neurol Clin (2015) 0.75
A Case Contradicting the Definition of Embolic Strokes of Undetermined Source: The Necessity of Transesophageal Echocardiography. J Clin Neurol (2016) 0.75
Atrial Cardiopathy and Cryptogenic Stroke: A Cross-sectional Pilot Study. J Stroke Cerebrovasc Dis (2015) 0.75
Percutaneous PFO closure for cryptogenic stroke in the setting of a systematic cardiac and neurological screening and a standardised follow-up protocol. Open Heart (2017) 0.75
Toward a better understanding of PFO and stroke risk. Neurology (2013) 0.75
Association of Left Atrial Enlargement with Cortical Infarction in Subjects with Patent Foramen Ovale. J Stroke (2016) 0.75
Endocardial Device Leads in Patients with Patent Foramen Ovale: Echocardiographic Correlates of Stroke/TIA and Mortality. Pacing Clin Electrophysiol (2016) 0.75
Recurrent Patent Foramen Ovale-Related Cerebral Infarcts Alternately Causing Bilateral Hand Paresis. Case Rep Neurol (2017) 0.75
Systematic Review of Treatment for Trapped Thrombus in Patent Foramen Ovale. Korean Circ J (2017) 0.75
Successful Percutaneous Transcatheter Patent Foramen Ovale Closure Through The Right Internal Jugular Vein Using Stiff Amplatzer Catheter With A Reshaped Tip. Del Med J (2016) 0.75
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke (1993) 29.81
Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med (2012) 8.19
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med (2001) 5.10
Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation (2002) 4.69
Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke (2009) 4.14
Conceptual problems in the definition and interpretation of attributable fractions. Am J Epidemiol (1988) 4.08
Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology (2000) 3.64
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials (2010) 3.45
Imputation is beneficial for handling missing data in predictive models. J Clin Epidemiol (2007) 3.08
Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke (2002) 2.96
Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc (1999) 2.80
Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke (2008) 2.60
Prevalence and repair of intraoperatively diagnosed patent foramen ovale and association with perioperative outcomes and long-term survival. JAMA (2009) 2.57
Patent foramen ovale and stroke. Circulation (2005) 2.34
Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA (2011) 2.27
Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study. J Am Coll Cardiol (2008) 1.85
Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke (2010) 1.83
Recurrent stroke on imaging and presumed paradoxical embolism: a cross-sectional analysis. Neurology (2012) 1.63
Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry (2002) 1.63
Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke (1998) 1.52
Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis (2009) 1.34
The risk of paradoxical embolism (RoPE) study: initial description of the completed database. Int J Stroke (2012) 1.32
On the relations between excess fraction, attributable fraction, and etiologic fraction. Am J Epidemiol (2012) 1.13
Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci (2007) 1.06
Patent foramen ovale and cryptogenic stroke. N Engl J Med (2008) 1.00
Cerebral emboli of paradoxical origin. Ann Neurol (1983) 0.99
Atherosclerotic burden findings in young cryptogenic stroke patients with and without a patent foramen ovale. Stroke (2008) 0.98
Feasibility and clinical utility of transesophageal echocardiography in the acute phase of cerebral ischemia. Am J Cardiol (2010) 0.92
Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J Neurol Sci (2008) 0.92
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med (2014) 12.79
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med (2013) 7.00
Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med (2015) 6.96
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Genome sequence and analysis of the Irish potato famine pathogen Phytophthora infestans. Nature (2009) 6.44
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ (2011) 4.71
Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation (2002) 4.69
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49
Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke (2006) 4.47
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
A predictive model for progression of chronic kidney disease to kidney failure. JAMA (2011) 4.22
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA (2008) 4.21
Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke (2009) 4.14
Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation (2005) 4.08
Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07
Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA (2007) 4.03
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA (2002) 3.65
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65
Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke (2004) 3.60
An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol (2009) 3.36
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke (2003) 3.18
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ (2003) 3.03
Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. Am J Med (2013) 3.03
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res (2008) 2.88
Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol (2010) 2.87
Blood pressure and vessel recanalization in the first hours after ischemic stroke. Stroke (2005) 2.78
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol (2008) 2.77
Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol (2005) 2.75
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet (2012) 2.69
Cardiovascular disease and subsequent kidney disease. Arch Intern Med (2007) 2.65
Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol (2005) 2.60
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke (2007) 2.55
Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens (2014) 2.54
Vertebral artery dissection: presenting findings and predictors of outcome. Stroke (2006) 2.52
Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study. Circulation (2012) 2.48
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43
Aortic arch plaques and risk of recurrent stroke and death. Circulation (2009) 2.40
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest (2003) 2.39
Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke (2005) 2.38
Predicting six-month mortality for patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol (2009) 2.38
Traditional risk factors are not major contributors to the variance in carotid intima-media thickness. Stroke (2013) 2.34
Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol (2005) 2.34
Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke (2009) 2.33
Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol (2004) 2.30
Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke (2007) 2.30
Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol (2002) 2.25
Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest (2007) 2.23
Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol (2010) 2.20
Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail (2011) 2.19
Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke (2006) 2.17
NIHSS score and arteriographic findings in acute ischemic stroke. Stroke (2005) 2.17
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet (2011) 2.16
Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis (2006) 2.16
Left ventricular mass and geometry and the risk of ischemic stroke. Stroke (2003) 2.15
Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol (2007) 2.15
Composite scaffold provides a cell delivery platform for cardiovascular repair. Proc Natl Acad Sci U S A (2011) 2.14
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13